1 The GABA modulating and GABA-mimetic actions of the general anaesthetic etomidate were examined in voltage-clamp recordings performed on Xenopus laevis oocytes induced, by cRNA injection, to express human recombinant g-aminobutyric acid A (GABA A ) receptor subunits. 2 Currents mediated by recombinant receptors with the ternary subunit composition a x b y g 2L (where x=1,2,3 or 6 and y=1 or 2), in response to GABA applied at the appropriate EC 10 , were enhanced by etomidate in a manner that was dependent upon the identity of both the a and b subunit isoforms. 3 For the b 2 -subunit containing receptors tested, the EC 50 for the potentiation of GABA-evoked currents by etomidate (range 0.6 to 1.2 mM) was little aected by the nature of the a subunit present within the hetero-oligomeric complex. However, replacement of the b 2 by the b 1 subunit produced a 9 ± 12 fold increase in the etomidate EC 50 (6 to 11 mM) for all a-isoforms tested. 4 For a 1 , a 2 and a 6 , but not a 3 -subunit containing receptors, the maximal potentiation of GABAevoked currents by etomidate was greater for b 2 -than for b 1 -subunit containing receptors. This was most clearly exempli®ed by receptors composed of a 6 b 1 g 2L compared to a 6 b 2 g 2L subunits, where a maximally eective concentration of etomidate potentiated currents evoked by GABA at EC 10 to 28+2% and 169+4% of the maximal GABA response, respectively. 5 For a 1 subunit-containing receptors, the potency and maximal potentiating eect of either pentobarbitone or propofol was essentially unaected by the b subunit isoform contained within the receptor complex. The potency of the anaesthetic neurosteroid 5a-pregnan-3a-ol-20-one was marginally higher for b 1 rather than the b 2 subunit-containing receptor, although its maximal eect was similar at the two receptor isoforms. 6 The GABA-mimetic action of etomidate was supported by b 2 -but not b 1 -subunit containing receptors, whereas that of pentobarbitone or propofol was evident with either b isoform. For b 2 -subunit containing receptors, both the agonist EC 50 and the maximal current produced by etomidate were additionally in¯uenced by the a isoform. 7 It is concluded that the subtype of b-subunit in¯uences the potency with which etomidate potentiates GABA-evoked currents and that the b isoform is a crucial determinant of the GABA-mimetic activity of this compound. The nature of the a-subunit also impacts upon the maximal potentiation and activation that the compound may elicit. Such pronounced in¯uences may aid the identi®cation of the site that recognises etomidate. More generally, these results provide a clear example of structural speci®city in anaesthetic action.
Introduction
The g-aminobutyric acid type A (GABA A ) receptor is an anion selective ligand-gated ion channel that mediates the majority of the inhibitory actions of GABA within the central nervous system. The receptor is composed of a pentamer of structurally homologous subunits which, in mammals, may be drawn from a 1 ± 6 , b 1 ± 3 , d and g 1 ± 3 subunit families (Sieghart, 1995; Smith & Olsen, 1995) . The precise subunit composition of GABA A receptor isoforms is an important determinant of their pharmacological and biophysical properties McKernan & Whiting, 1996) . Drugs that selectively potentiate GABA-ergic neurotransmission, or include such an action within a wider spectrum of eects, can produce behavioural actions that include anxiolytic, anti-convulsant, sedative, and, most strikingly, general anaesthetic actions (Sieghart, 1995) . Although the latter has traditionally been linked to the ability of anaesthetic molecules to partition into the lipid phase of the plasma membrane (Franks & Lieb, 1994; Little, 1996) to eect changes in membrane¯uidity or volume, there is now an impressive corpus of evidence demonstrating that the majority of clinically useful and experimental anaesthetics potentiate the actions of GABA at the GABA A receptor (Tanelian et al., 1993; Franks & Lieb, 1994; Lambert et al., 1995) .
The sheer diversity of anaesthetic structures that modulate GABA A receptor function, when combined with exquisite structure activity requirements within certain classes of agent, such as the pregnane steroids (Lambert et al., 1995) , militates against the existence of a common binding site for these agents. Furthermore, the eects of binary combinations of chemically distinct general anaesthetics on GABA A receptor function, support the presence of discrete binding domains on the receptor protein for these agents (e.g. Hales & Lambert, 1991; Belelli et al., 1996) . The interaction of benzodiazepines with the GABA A receptor is dependent upon its subunit composition (Smith & Olsen, 1995) . This information, together with that obtained from domain exchange and site-directed mutagenesis experiments, has allowed for the tentative identi®cation of the amino acids which may contribute to the benzodiazepine binding pocket (Smith & Olsen, 1995) . By contrast, equivalent studies with general anaesthetics such as the barbiturates and the steroids did not initially reveal an absolute subunit preference and as a consequence there has been little progress in determining the structural determinants of anaesthetic binding to the GABA A receptor. However, more recently a distinctive interaction of anaesthetic steroids with a 6 -subunit-containing receptors and pentobarbitone and propofol with a 4 -and a 6 -subunit-containing receptors has been reported Thompson et al., 1996; Waord et al., 1996) . Furthermore, the dierential interaction of anaesthetics with an invertebrate recombinant GABA receptor (Chen et al., 1994; Belelli et al., 1996) and the insensitivity of the retinal r-subunit (Cutting et al., 1991) to intravenous anaesthetics (Shimada et al., 1992; Mihic & Harris, 1996) may oer alternative approaches for future investigations.
The interaction of the general anaesthetic etomidate with dierent GABA A receptor isoforms has not been investigated systematically. This anaesthetic is utilized clinically, partly as a consequence of its lack of eect upon sympathetic out¯ow and autonomic re¯exes during induction (Ebert et al., 1992) . Early electrophysiological studies demonstrated a GABA-mimetic action of this anaesthetic in spinal cord and autonomic ganglia (Evans & Hill, 1978) and GABA-modulated actions in hippocampal slices (Ashton & Wauquier, 1985) . Voltage-clamp experiments in which both recombinant and native GABA A receptors were used con®rmed that low concentrations of etomidate potentiate GABA-evoked currents and higher concentrations are GABA-mimetic (Robertson, 1989; Belelli et al., 1996) . At the single channel level, concentrations of the anaesthetic which may approximate to those achieved clinically, have no eect upon the elementary conductance of GABA A receptors of rat hippocampus, but produce a prolongation of the receptor-channel open time and opening frequency (Olsen et al., 1986; Ticku & Rastogi, 1986; Slany et al., 1995) .
We have previously demonstrated that etomidate enhances GABA-evoked currents recorded from Xenopus laevis oocytes expressing the human a 3 b 1 g 2L recombinant subunit combination . However, the anaesthetic did not activate the GABA A receptor complex, a feature readily demonstrable with mammalian native GABA A receptors (Robertson, 1989; Belelli et al., 1996) . One interpretation of these disparate ®ndings is that the interaction of etomidate is subunit speci®c. Here, we demonstrate that both the GABA-modulatory and GABA-mimetic actions of this anaesthetic are dictated by the subunit complement of the GABA A receptor. Since the receptor composition varies between CNS structures McKernan & Whiting, 1996) , it can be anticipated that the physiological actions of etomidate will exhibit a regional selectivity that may contribute to its anaesthetic pro®le. In addition, the subunit-selective action of etomidate might, in the future, allow a better de®nition of the anaesthetic binding domain on the receptor protein.
Methods

Preparation of transcripts and oocyte injection
cDNAs encoding the human a 1 , a 2 , a 3 , a 6 , b 1 , b 2 and g 2L GA-BA A receptor subunits (obtained from Dr P. Whiting, Merck, Sharp and Dohme, Harlow, U.K.) were linearized by use of the appropriate restriction enzymes in the pCDM8 vector. cRNA transcripts were prepared according to standard protocols (Hope et al., 1993) . The integrity of the transcripts was determined by electrophoresis through a 1% agarose/formaldehyde gel alongside standard RNA size markers. cRNA transcripts were injected (50 nl of 1 mg ml 71 cRNA per subunit) into Xenopus laevis oocytes (stage V ± VI) which had been defolliculated by a 2 ± 3 h incubation at 18 ± 238C in a Ca 2+ -free Barth's saline supplemented with 2 mg ml 71 collagenasè A' (Boehringer-Mannheim). Injected oocytes were subsequently maintained at 19 ± 208C for up to 12 days in 96 well microtitre plates containing 200 ml of Barth's saline (composition in mM: NaCl 88, KCl 1, NaHCO 3 24, MgSO 4 1, CaCl 2 0.5, Ca(NO 3 ) 2 0.5, HEPES 15; pH 7.5) supplemented with gentamicin (1 mg ml 71 ).
Electrophysiological recordings
Electrophysiological experiments with oocytes were conducted 2 ± 12 days after cRNA injection. Agonist evoked currents were recorded under voltage-clamp at a holding potential of 760 mV by an Axoclamp 2A ampli®er (Axon Instruments, U.S.A.) in the two electrode voltage-clamp recording mode. The voltage-sensing and current-passing electrodes were ®lled with 3 M KCl and had resistances of 0.5 ± 1.5 MO when measured in extracellular recording solution containing (in mM): NaCl 120, KCl 2, CaCl 2 1.8 and HEPES-NaOH 5 (pH 7.4). Oocytes held in a 0.5 ml chamber were continuously superfused with this solution at a rate of 7 ± 10 ml min 71 , and all agonist, antagonist and modulating drugs were applied via their inclusion within the superfusate, Agonist-evoked currents were low-pass ®ltered at a corner frequency of 200 Hz (Bessel characteristic) and stored on magnetic or digital audio tape with a Racal Store 4DS FM tape recorder or Biologic DAT 1204 recorder respectively, and simultaneously displayed on a chart recorder. All experiments were performed at ambient temperature (18 ± 228C).
The agonist potency of GABA at recombinant GABA A receptors composed of a X b Y and g 2L subunits (where a X is a 1 , a 2, , a 3 or a 6 , and b Y is b 1 or b 2 ) is aected by the composition of the hetero-oligomeric complex (Ebert et al., 1994) . For several anaesthetic agents which act as positive allosteric modulators of GABA A receptor mediated currents, potentiation involves an apparent increase in agonist anity (Harris et al., 1995; Belelli et al., 1996) . To provide a quantitative comparison of the modulating eects of anaesthetic agents at GABA A receptors of diering subunit composition and apparent anity towards GABA, it was therefore necessary to utilize concentrations of agonist that produced an equivalent, submaximal, response. For each oocyte and hetero-oligomeric receptor examined, the maximal peak current response to a saturating concentration of GABA (3 mM) was ®rst determined and shown to be stable over time . The concentration of GABA which evoked a response amounting to 10% of the maximal current (i.e. EC 10 ) was subsequently determined and employed to investigate the effects of the modulating agents. Positive allosteric regulation was quanti®ed as the increase in the peak amplitude of the GABA-evoked current and data were normalized by expressing the observed response as a percentage of the maximal GABA response. Anaesthetics were pre-applied for 30 ± 60 s before their co-application with the appropriate concentration of GABA. Potential agonist actions of the anaesthetics were investigated in the absence of GABA and, where evident, responses were expressed as a percentage of the maximal response to GABA. Concentration-eect relationships for either the GABA-modulating or GABA-mimetic actions of the anaesthetics were iteratively ®tted, by use of Fig P version 
Drugs used
g-Aminobutyric acid, sodium pentobarbitone and picrotoxin (all Sigma) were freshly prepared as stock solutions in saline. A concentrated stock solution of propofol (2,6-diisopropylphenol, 300 mM, Aldrich) was prepared in 100% ethanol, whereas concentrates (10 mM) of¯unitrazepam and 5a-pregnan-3a-ol-20-one (both Sigma) were prepared in 100% dimethylsulphoxide as the solvent. Etomidate was obtained from Janssen as a concentrate in alcohol (Hypnomidate for injection, containing etomidate chloride equivalent to 125 mg etomidate free base ml
71
) and the concentrate was diluted into saline. The maximal ®nal vehicle concentration for these drugs was 0.2% vol/vol, which was without eect in the presence, or absence, of GABA.
Results
The in¯uence of the b isoform on the actions of etomidate at the GABA A receptor
For oocytes expressing the a 1 b 2 g 2L subunit combination, etomidate produced a concentration-dependent enhancement of the inward current response induced by the bath application of GABA at EC 10 ( Figure 1 ). The calculated EC 50 for etomidate, determined over the range 10 nM ± 30 mM, was 1.2+0.1 mM and maximal potentiation (127+12% of the GABA maximum; n=4) was produced by 30 mM of the anaesthetic ( Figure  1 , Table 1 ). A higher concentration of etomidate (100 mM) was associated with a potentiation of reduced magnitude, giving rise to a bell-shaped concentration-response relationship. At concentrations greater than those required to produce a substantial enhancement of the GABA-mediated response, etomidate (10 ± 300 mM), in the absence of GABA, evoked an inward current response (Figures 1 and 2, Table 1) which was enhanced by¯unitrazepam (300 nM) and antagonized by picrotoxin (30 mM), con®rming the involvement of GABA A receptors in this eect. The calculated EC 50 of etomidate for this direct eect was 83+34 mM and the maximal current evoked by 300 mM of the anaesthetic was 19+2% (n=4) of that induced by a saturating concentration of GABA ( Figure 1 ; Table  1 ). Concentrations of etomidate4300 mM elicited a complex response consisting of an initial peak, followed by a decline which was succeeded upon wash-out by the transient redevelopment of an inward current ( Figure 2 ). The latter, which has previously been observed for native GABA A receptors, might be attributable to a low anity blockade of the chloride channel by etomidate which reverses upon washout before the dissociation of the drug from a higher anity agonist site (Robertson, 1989) .
Etomidate also potentiated GABA-evoked currents recorded from oocytes expressing the a 1 b 1 g 2L subunit combination ( Figure 1 and Table 1 ). However, the calculated EC 50 value for etomidate (determined over the range 300 nM ± 100 mM) was approximately 9 fold greater than that derived for the a 1 b 2 g 2L subunit combination (P50.005, Figure 1 , Table 1 ). Furthermore, the maximal potentiation produced by 100 mM etomidate (79+2% of the GABA maximum; n=4) was less than the maximal eect of the anaesthetic on the b 2 subunitcontaining receptor (P50.005, Figure 1 , Table 1 ). A higher concentration of etomidate (300 mM) was associated with a potentiation of reduced magnitude (cf. 100 mM for the a 1 b 1 g 2L subunit combination; Figure 1 ). In contrast to the a 1 b 2 g 2L subunit combination, the b 1 subunit-containing receptor appeared relatively insensitive to the direct eects of this anaesthetic. Hence, even a high concentration (1 mM) of etomidate induced a current amounting to only 4+1% of the GABA maximum (n=4). The small magnitude of these currents precluded the calculation of an EC 50 for this direct eect of etomidate. Furthermore, at these high concentrations (1 ± 3 mM), only a proportion (*50%) of this small direct current was blocked by picrotoxin (30 mM) suggesting a component of the response to be mediated by a non-speci®c action of etomidate. Indeed, un-injected oocytes exhibited small inward currents to high concentrations (3 mM) of etomidate (data not shown). Hence, in summary, replacement of the b 2 by the b 1 subunit in the ternary subunit complex a 1 b X g 2L reduced the modulating Figure 1 The isoform of the b subunit in¯uenced both the GABAmodulating and GABA-mimetic actions of etomidate. (a) Traces illustrating the concentration-dependent enhancement by etomidate (1 ± 100 mM) of the inward current evoked by GABA, at EC 10 , bathapplied to Xenopus laevis oocytes expressing the human a 1 b 1 g 2L receptor combination. In this and subsequent illustrations, periods of drug application are indicated by the horizontal bars above the current records. (b) Comparative records depicting enhancement by etomidate (300 nM ± 30 mM) of GABA (EC 10 )-evoked currents recorded from oocytes expressing the a 1 b 2 g 2L receptor combination. Note that the anaesthetic is a more potent modulator of the a 1 b 2 g 2L subunit combination and, that at the highest concentration of etomidate tested (30 mM), there is evidence of a small inward current before the co-application of GABA. (c) Graphical depiction of the relationship between the concentration of etomidate in the medium (logarithmic scale) and the peak amplitude of the GABA-evoked current (on a linear scale and expressed relative to the maximum current induced by a saturating concentration (3 mM) of GABA). Data show the potentiation of GABA at the a 1 b 1 g 2L (&) and the a 1 b 2 g 2L (*) receptors. Additionally, the peak direct current elicited by etomidate alone at the a 1 b 2 g 2L receptor (~) is plotted. Little or no direct current was evident for the a 1 b 1 g 2L receptor. Each point represents the mean of data obtained from 4 ± 5 oocytes, which were voltage-clamped at a holding potential of 760 mV; vertical lines show s.e.mean. Note that the EC 50 values for etomidate (and other anaesthetics) quoted in the text and Table 1 were calculated from curve ®ts restricted to the ascending limb of the concentration-eect relationship. Curves illustrated in this and subsequent ®gures were ®tted`free-hand' and have no theoretical signi®cance. potency and maximal potentiating eect of etomidate. Furthermore, the ability of the anaesthetic to activate directly the GABA A receptor-channel complex was dramatically reduced.
Pentobarbitone, propofol and 5a-pregnan-3a-ol-20-one are not in¯uenced by the isoform of the b subunit
We further investigated whether the subtype of b subunit similarly in¯uenced the interaction of the structurally diverse anaesthetics pentobarbitone, propofol and 5a-pregnan-3a-ol-20-one with the GABA A receptor. Pentobarbitone (1 ± 300 mM) produced a concentration-dependent potentiation of GABAevoked currents recorded from ooyctes expressing either a 1 b 2 g 2L or a 1 b 1 g 2L receptor subunit combinations (Figure 3) . However, in contrast to etomidate, neither the calculated EC 50 value for pentobarbitone (55+4 mM for a 1 b 2 g 2L ; 65+3 mM for a 1 b 1 g 2L ), nor the maximal potentiation produced (128+7%; n=4 for a 1 b 2 g 2L ; 117+9% of the GABA maximum; n=3 for a 1 b 1 g 2L ) was in¯uencend by the nature of the b subunit isoform (Figure 3 ). In the absence of GABA, pentobarbitone (100 mM ± 6 mM) evoked a concentration-dependent inward current on oocytes expressing either subunit combination (Figure 3) . Such currents were inhibited by picrotoxin (30 mM) and potentiated by¯unitrazepam (300 nM; not shown) implicating the GABA A receptor in this eect. However, in contrast to etomidate, neither the EC 50 for pentobarbitone (0.6+0.08 mM for a 1 b 2 g 2L ; 1.1+0.02 mM for a 1 b 1 g 2L ), nor the maximal current produced (16+1%; n=3 for a 1 b 2 g 2L ; 16+1% of the GABA maximum, n=3 for the a 1 b 1 g 2L receptor combination) were much in¯uenced by the b isoform.
Propofol (30 nM ± 30 mM) produced a concentration-dependent enhancement of GABA-evoked currents recorded from oocytes expressing either the a 1 b 2 g 2L or a 1 b 1 g 2L receptor subunit combinations (Figure 3) . The calculated EC 50 for propofol (7+0.3 mM, for a 1 b 2 g 2L ; 4+0.7 mM for a 1 b 1 g 2L ), was similar for either b isoform. The maximal eect of propofol at b 2 subunit-containing receptors (127+5% of the GABA maximum; n=4) was somewhat greater than that observed at b 1 subunit-containing receptors (95+2% of the GABA maximum; n=5; P50.01; Figure 3 ). In the absence of GABA, propofol (10 ± 300 mM) evoked a concentration-dependent inward current on oocytes expressing receptors containing either Figure 2 Etomidate directly activated the human a 1 b 2 g 2L receptor. Bath applied etomidate (30 mM ± 1 mM) induced a concentrationdependent inward current when applied to oocytes expressing the a 1 b 2 g 2L receptor. Note that at the higher concentrations of the anaesthetic tested (5300 mM) the current faded in the continued presence of the agonist. With 600 mM and 1 mM etomidate, redevelopment of the inward current was apparent upon wash-out of the drug. (b) The current induced by 100 mM etomidate was enhanced by the co-application of¯unitrazepam (300 nM) and antagonized by picrotoxin (30 mM). All records were obtained at a holding potential of 760 mV.
b isoform. Currents evoked by propofol were blocked by picrotoxin (30 mM) and enhanced by¯unitrazepam (300 nM; not shown). Again, in contrast to etomidate, neither the propofol EC 50 (47+1 mM for a 1 b 2 g 2L ; 46+1 mM for a 1 b 1 g 2L ), nor the maximal eect (48+8%, n=3 for a 1 b 2 g 2L ; 37+2%, n=5 for a 1 b 1 g 2L of the GABA maximum) were much in¯uenced by the b isoform (Figure 3) . The neurosteroid anaesthetic 5a-pregnan-3a-ol-20-one is established as a potent allosteric modulator of the GABA A receptor (Lambert et al., 1995) . Here, 5a-pregnan-3aol-20-one (3 nM ± 1 mM) produced an enhancement of GABA-evoked currents recorded from oocytes expressing a 1 b 2 g 2L or a 1 b 1 g 2L receptors. The calculated EC 50 for this eect was 177+2 nM and 89+6 nM for a 1 b 2 g 2L and a 1 b 1 g 2L receptors, respectively (not shown). Hence, in contrast to etomidate, the steroid is slightly more potent at the b 1 -containing receptor. The maximum potentiation produced (75+4%, n=4 for a 1 b 2 g 2L receptors and 69+4% of the GABA maximum, n=6 for a 1 b 1 g 2L receptors) is not in¯uenced by the b isoform (not shown). We have previously shown that the direct eect of this neurosteroid is small (*1% of the GABA maximum; see Belelli et al., 1996) . Therefore, no attempt was made to compare the in¯u-ence of the b subtype on this aspect of neurosteroid action.
The in¯uence of the a isoform on the actions of etomidate at the GABA A receptor
The results above clearly demonstrate that for a 1 subunitcontaining receptors, the interaction of etomidate is in¯uenced by the isoform of the b subunit. The impact of changing the subtype of the a subunit on the actions of this anaesthetic for b 1 -and b 2 -containing receptors was additionally investigated. The EC 50 for the GABA modulating action of etomidate was little in¯uenced by the subtype of a subunit (a=2, 3 or 6) assembled within either b 1 g 2L or b 2 g 2L subunit-containing receptors (Table 1, Figures 4 and 5) . However, consistent with the results obtained for a 1 subunit-containing receptors, a comparison of a x b 2 g 2L with a x b 1 g 2L receptors (where x=2, 3 or 6) revealed the etomidate EC 50 to be 7 to 12 fold greater for the b 1 -compared to b 2 -containing receptors (P50.005). Furthermore, similar to a 1 , for a 2 and a 6 the maximal enhancement produced by the anaesthetic was greater for the b 2 -compared with the b 1 -containing receptors (P50.0001, Table 1 , Figures 4  and 5 ). This dierence is most marked when the b subunit is coexpressed with the a 6 subunit (169+14%, n=5, for the a 6 b 2 g 2L ; 28+2% of the GABA maximum for a 6 b 1 g 2L , n=4; Figure 5 ). For a 3 -containing receptors, the replacement of the b 1 by the b 2 subunit produced an 8 fold decrease of the etomidate EC 50 , but it had little in¯uence on the maximal potentiation produced (P40.1, Figure 4 , Table 1 ). Hence, although for a 1 , a 2 and a 6 both the potency and maximal eect of etomidate are greater for the b 2 -compared to b 1 -containing receptors, the result obtained with the a 3 subunit suggests that these two properties are not intrinsically linked.
For all b 2 subunit-containing receptors (a x b 2 g 2L where x=2, 3 or 6) etomidate, in the absence of GABA, evoked a concentration-dependent inward current that was blocked by picrotoxin (30 mM, not shown). By contrast, etomidate produced little or no eect on the corresponding b 1 subunit-containing receptors (Figures 4 and 5, Table 1 ). Both the agonist potency of etomidate and the maximal eect produced were clearly Concentration of etomidate (M) % maximum GABA response Figure 4 The interaction of etomidate with a 2 -and a 3 -containing receptors was in¯uenced by the b isoform. The graphs illustrate the relationship between the concentration of etomidate (logarithmic scale) and the GABA (EC 10 )-evoked current (on a linear scale and expressed relative to the maximum current induced by a saturating concentration (3 mM) of GABA) for a 2 subunit-containing and a 3 subunit-containing receptors. Data show the potentiation of GABA at the a 2 b 2 g 2L (*) and the a 3 b 2 g 2L (*) and a 2 b 1 g 2L (&) and a 3 b 1 g 2L (&) receptors. Additionally, the peak direct current elicited by etomidate alone is plotted for both the a 2 b 2 g 2L (~) and the a 3 b 2 g 2L (~) receptors. Little current was observed for the a 2 b 1 g 2L receptor and etomidate induced no current for the a 3 b 1 g 2L receptor. Each point represents the mean of data obtained from 4 ± 5 oocytes, which were voltage-clamped at 760 mV; vertical lines show s.e.mean.
in¯uenced by the a isoform and followed the same rank order (a 6 b 2 g 2L 4a 2 b 2 g 2L 4a 1 b 2 g 2L 4a 3 b 2 g 2L ). In summary, the b 1 subunit-containing receptor does not mediate a robust direct eect of etomidate. However, for b 2 subunit-containing receptors, both the potency and the maximal eect are additionally inuenced by the a subunit isoform.
Discussion
In the present study, etomidate potentiated, in a concentration-dependent manner, GABA-evoked currents mediated by any of the recombinant GABA A receptors examined. However, both the potency and the magnitude of this eect were clearly dependent on the subtype of the b subunit (b 1 or b 2 ) expressed within the hetero-oligomeric complex. Hence, for all a subunits examined (a 1,2,3 and 6 ), etomidate was consistently more potent (7 ± 12 fold) at b 2 compared to b 1 subunit-containing receptors. In preliminary experiments, the GABAmodulating action of etomidate at the a 6 b 3 g 2L receptor was found to be similar to that of the corresponding b 2 subunitcontaining receptor (D. Belelli, unpublished observations). In contrast to this clear selectivity for b 2 or b 3 subunit-containing receptors, a comparison of the subtype of a subunit within either b 1 -or b 2 -containing receptors revealed little or no inuence of the a subtype on the modulating potency of the anaesthetic. With the exception of a 3 subunit-containing receptors, the maximal enhancement of the GABA-evoked current produced by etomidate was greater for the b 2 -than the b 1 -containing receptors. This dierence is most marked for a 6 b 1 g 2L in comparison to a 6 b 2 g 2L receptors. However, the example of a 3 -containing receptors would suggest the increased maximal eect and the apparent anity of etomidate for the modulating site are not intrinsically linked. The role of the g subunit on the GABA modulating actions of etomidate has not been systematically investigated, although an electrophysiological study of HEK293 cells expressing a 1 b 1 and a 1 b 1 g 2s subunits revealed that the g 2 subunit is not essential for activity, but may in¯uence the nature of the pertubation of GABA A receptor channel kinetics by the anaesthetic (Uchida et al., 1995) . In summary, the subtype of b subunit is a major determinant of the modulating actions of etomidate, although for some receptors the a subtype may also in¯uence this interaction. The in¯uence of the isoform of the g subunit remains to be determined.
Although the present investigation was limited to receptors incorporating the a 1 subunit subtype, the nature of the b subunit appeared to exhibit little in¯uence upon the potency, or the maximal eect, of propofol, pentobarbitone or 5a-pregnan-3a-ol-20-one to potentiate GABA-evoked responses (see also Hadingham et al., 1993) . Hence, the clear b 2 selective actions of etomidate are not shared by propofol, pentobarbitone or 5a-pregnan-3a-ol-20-one. These observations suggest that the modulator binding sites for these anaesthetics are distinct from the etomidate site. In support of this proposal, we have recently demonstrated that pentobarbitone and propofol, but not etomidate, act as positive allosteric modulators of a recombinant GABA receptor isolated from Drosophila melanogaster, whereas 5a-pregnan-3a-ol-20-one exerts a modest allosteric action at this invertebrate receptor (Chen et al., 1994; Belelli et al., 1996) .
Previous investigations on native mammalian GABA A receptors have shown that etomidate, at concentrations generally greater than those required for GABA modulation, can directly activate GABA A receptors in a picrotoxin-and bicuculline-sensitive manner (Evans & Hill, 1987; Robertson, 1989) . In common with the GABA modulating eects of the anaesthetic, the GABA-mimetic action of etomidate is highly dependent upon the b subunit. Indeed, like pentobarbitone and propofol, etomidate can directly activate murine homomeric b 2 or b 3 GABA A receptors expressed in Xenopus oocytes (Cestari et al., 1996) . Therefore, the agonist binding site for etomidate is clearly represented on these isoforms of b subunit. The GABA A , like the nicotinic, receptor is thought to be composed of ®ve subunits. For the majority of native GABA A receptors, at least three classes of subunit are proposed to contribute to the hetero-oligomeric complex (McKernan & Whiting, 1996) . In the case of recombinant ternary receptors, the GABA-mimetic actions of etomidate are critically dependent on the presence of the b 2 subunit isoform and are minimal, or absent, for b 1 -containing receptors. In preliminary Figure 5 The isoform of the b subunit greatly in¯uenced both the GABA-modulating and GABA-mimetic actions of etomidate for a 6 -containing receptors. (a) Etomidate (1 ± 100 mM) produced a concentration-dependent, but modest, enhancement of the inward current produced by GABA, bath applied at EC 10 , to Xenopus laevis oocytes expressing the human a 6 b 1 g 2L receptor combination. (b) In comparison, at a 6 b 2 g 2L receptors, much lower concentrations of etomidate (100 nM ± 30 mM) enhanced GABA (EC 10 ) evoked currents and produced a much greater maximal potentiation. (c) Graph illustrating the relationship between the concentration of etomidate (logarithmic scale) and the current elicited by GABA at EC 10 (on a linear scale and expressed relative to the maximum current induced by a saturating concentration (3 mM) of GABA). Data show the potentiation of GABA at the a 6 b 1 g 2L (&) and the a 6 b 2 g 2L (*) receptors. Additionally, the peak direct current elicited by etomidate alone at the a 6 b 2 g 2L receptor (~) is plotted. Little or no direct current was evident for the a 6 b 1 g 2L receptor. Each point represents the mean of data obtained from 4 ± 6 oocytes, which were voltageclamped at 760 mV; vertical lines show s.e.mean.
Etomidate
Loreclezole Figure 6 The chemical structures of etomidate and loreclezole.
experiments, we found the agonist actions of etomidate to be supported by b 3 -containing ternary receptors (D. Belelli, unpublished observations). Therefore, the b isoform aects both the GABA-modulating and GABA-mimetic actions of this anaesthetic, but does not in¯uence the GABA-modulating or GABA-mimetic actions of pentobarbitone or propofol. For b 2 subunit-containing receptors, the EC 50 for the direct activation of the GABA A receptor channel complex by etomidate was in¯uenced by the a isoform (range*22 ± 130 mM for a 1 -and a 6 subunit-containing receptors), whereas the GABA modulating eect was not. Additionally, for b 2 -containing receptors, the magnitude of the etomidate-induced current was dependent upon the a subtype (e.g. maximal eect=9% and 51% of the maximum response to GABA for the a 3 -and a 6 -containing receptors, respectively; see Table 1 ). These data strongly suggest that the interaction of this anaesthetic with native GABA A receptors will be dependent upon the a and b subunit isoform expressed within the pentameric complex. The pharmacological selectivity of etomidate (Shepherd et al., 1996) makes it likely that the GABA A receptor class is an important mediator of the anaesthetic eect of the agent. Indeed, the EC 50 values determined for the potentiating, but not GABA-mimetic, actions of etomidate at b 2 subunit-containing receptors (range 0.6 to 1.2 mM) are close to the plasma concentration (approximately 2 mM) of the drug required to maintain anaesthesia in patients in which opioid analgesics were coadministered (Fragen et al., 1983) . However, the free concentration of etomidate in plasma is likely to be considerably lower than this value due to extensive protein binding of the drug (Meuldermans & Heykants, 1976) . Conversely, following a bolus injection, the concentration of etomidate in the brain exceeds that measured in plasma (Heykants et al., 1975) . In view of these facts, it would be unwise to attach too great a signi®cance to the concordance between plasma concentrations of the drug associated with anaesthesia and those aecting b 2 subunit-containing GABA A receptors. The dierential susceptibility of GABA A receptor isoforms to allosteric regulation by etomidate may impart a degree of regional selectivity in its actions. A precedent is provided by a 6 subunit-containing receptors which are con®ned to the granule cells of the cerebellum. A strain of rats has been identi®ed which exhibit pronounced postural impairment and ataxia to benzodiazepines (Korpi et al., 1993) . Normally, a 6 -containing receptors are insensitive to the positive allosteric modulating actions of certain benzodiazepines. However, genetic analysis of these rats reveals a single amino acid mutation of the a 6 subunit which confers sensitivity to such benzodiazepines (Korpi et al., 1993) . Collectively, these observations suggest that a 6 -containing GABA A receptors may play an important role in cerebellar motor control and its pertubation by drugs. The a 6 b X g 2 subunit combination is well represented in the rat cerebellum, where the b 1 subunit is a minor component compared to the b 2 and b 3 subunits Behringer et al., 1996; McKernan & Whiting, 1996) . Hence, it is probable that cerebellar granule cells express GABA A receptors (a 6 b 2 or 3 g 2 ) which are exceptionally sensitive to both the GABA-modulating and GABA-mimetic actions of etomidate (Table 1, Figure 5) .
Clearly, the relative slow application of submaximal concentrations of GABA to an oocyte does not reproduce the situation thought to occur at many central GABA-ergic synapses, where the release of neurotransmitter is rapid and may brie¯y saturate a relatively small number of postsynaptically located GABA A receptors (Mody et al., 1994) . These features restrict the mechanisms by which positive allosteric modulators of the GABA A receptor can act to enhance fast inhibitory neurotransmission within the central nervous system. Under those conditions, such compounds produce a prolongation of the duration of the inhibitory postsynaptic current (i.p.s.c.) rather than an augmentation of i.p.s.c. peak amplitude (Mody et al., 1994) . The application of whole-cell clamp techniques may provide an understanding of the role of the a 6 subunit in the inhibitory circuitry of the cerebellum (e.g. Tia et al., 1996) . It would now be of interest to investigate the in¯uence of etomidate on granule cell miniature i.p.s.cs to determine whether the clear GABA A receptor subtype selectivity evident in experiments with recombinant receptors has a functional consequence for synaptic transmission.
The clear selectivity of etomidate for b 2 and b 3 over b 1 subunit-containing receptors is reminiscent of the situation for the positive allosteric actions of the anticonvulsant loreclezole . Indeed, the structures of etomidate and loreclezole are similar ( Figure 6 ). The preference of loreclezole for the b 3 and b 2 rather than the b 1 subunit appears to be endowed by a single amino acid (an asparagine residue within b 2 and b 3 and a homologous serine residue within b 1 ) located towards the extracellular side of the M2 domain of the subunit, a region thought to form the lining of the associated chloride ion channel . Mutation of this amino acid to a serine residue (as in b 1 ) results in a reduction of the sensitivity to loreclezole, whereas mutation of the equivalent serine residue of a b 1 subunit to an asparagine enhances loreclezole sensitivity . The recent observation that the positive allosteric actions associated with relatively high concentrations of the b-carboline methyl-6,7-dimethoxy-4-ethyl-b-carboline (DMCM; Stevenson et al., 1995) are similarly in¯uenced by this residue highlights this domain as an important modulator locus for drug action. It would clearly be of interest to examine the impact of the above mutation upon the sensitivity of the GABA A receptor towards etomidate. If etomidate and loreclezole do indeed share a common site of action, it remains to be explained why the former possesses anaesthetic activity but the latter does not. Of potential relevance are the limited potentiation of GABA A receptor-mediated currents that can be achieved with loreclezole in comparison to etomidate (Waord et al., 1994; D. Belelli, unpublished observations) and the absence of a GABA-mimetic action for the former compound (Waord et al., 1994) .
In conclusion, the molecular interactions of the general anaesthetic etomidate with the GABA A receptor are subunit selective. It remains to be determined whether the primary in¯uence of the b isoform subtype is on the anaesthetic binding site, the transduction process, or both. Nevertheless, these observations appear counter-intuitive to a mechanism which invokes a non-speci®c membrane perturbation by the anaesthetic to produce a secondary change in receptor function.
